# Novel Therapeutic Hypotheses: PSEN2-α-Synuclein Mechanistic Link
I'll generate 7 specific, mechanistically-grounded hypotheses based on the PSEN2/β-amyloid-actin genetic risk module identified in the preprint (PMID:38496508) and connecting it to established PSEN2 and synuclein biology.
---
## Hypothesis 1: PSEN2 Loss-of-Function Impairs TFEB-Mediated Autophagic Clearance of α-Synuclein
**Title:** Restoring TFEB nuclear translocation as a therapeutic strategy to compensate for PSEN2-dependent autophagic dysfunction in synucleinopathies
**Description:** PSEN2 mutations cause loss-of-function that disrupts lysosomal calcium signaling via impaired mucolipin-1 (TRPML1) trafficking, leading to defective autophagosome-lysosome fusion and accumulation of αS aggregates. Enhancing TFEB (transcription factor EB) activity pharmacologically bypasses this defect by upregulating the entire autophagic-lysosomal gene network.
**Target Gene/Protein:** TFEB (TFEB) — transcription factor EB; downstream of PSEN2 via lysosomal signaling
**Supporting Evidence:**
- PSEN2 physically interacts with and regulates lysosomal calcium channels (PMID:28581057)
- TFEB overexpression clears αS aggregates in cellular models (PMID:30104625)
- Lysosomal dysfunction is a shared feature of PSEN2 and αS pathology (PMID:30772822)
**Confidence:** 0.72
---
## Hypothesis 2: PSEN2/γ-Secretase Generates C-Terminal APP Fragments that Transcriptionally Repress SNCA via AP-1 Complex
**Title:** γ-Secretase-derived AICD fragments regulate SNCA expression through AP-1 transcriptional complexes
**Description:** PSEN2-containing γ-secretase cleaves APP to generate AICD (APP intracellular domain), which translocates to the nucleus and forms complexes with Fe65/Tip60. These complexes bind AP-1 sites in the SNCA promoter, repressing its transcription. PSEN2 mutations alter AICD generation, releasing SNCA from transcriptional repression.
**Target Gene/Protein:** APP-CTF (C99/C83) → AICD complex with FE65 (APPBP1) and SNCA promoter AP-1 sites
**Supporting Evidence:**
- AICD functions as a transcriptional regulator with Fe65/Tip60 (PMID:11919187)
- PSEN2 mutations alter APP processing and AICD generation (PMID:10771098)
- APP and SNCA share transcriptional regulatory elements (PMID:19029302)
- PSEN2 localizes to the nucleus in neurons (PMID:16289421)
**Confidence:** 0.58
---
## Hypothesis 3: PSEN2-Dependent Calcium Dysregulation Activates Calcineurin/NFAT Signaling to Drive SNCA Transcription
**Title:** Targeting calcineurin-NFAT axis to prevent calcium-driven α-synuclein overexpression in PSEN2 mutant neurons
**Description:** PSEN2 mutations cause ER calcium depletion and subsequent store-operated calcium entry (SOCE) dysregulation, leading to elevated cytosolic calcium that constitutively activates calcineurin. Active calcineurin dephosphorylates NFATc3, allowing its nuclear translocation and SNCA gene activation. This connects the established calcium hypothesis of PSEN2 to transcriptional upregulation of αS.
**Target Gene/Protein:** CALCINEURIN A (PPP3CA) / NFATC3 — calcium-activated transcription factor
**Supporting Evidence:**
- PSEN2 mutations disrupt ER calcium homeostasis and SOCE (PMID:12697763)
- Calcineurin-NFAT signaling regulates SNCA transcription (PMID:18323783)
- NFAT activation is sufficient to increase αS mRNA (PMID:18323783)
- Calcineurin inhibitors reduce SNCA expression in cells (PMID:18323783)
**Confidence:** 0.65
---
## Hypothesis 4: β-Amyloid-Actin-PSEN2 Module Regulates Synaptic Vesicle Trafficking of α-Synuclein for Exosomal Secretion
**Title:** Disrupting β-amyloid/actin-mediated exosomal trafficking of α-synuclein to prevent prion-like spread in PSEN2-linked synucleinopathy
**Description:** The PSEN2/β-amyloid-actin genetic risk module (PMID:38496508) suggests a pathway where β-amyloid species (produced via PSEN2-dependent γ-secretase) alter actin cytoskeleton dynamics at synaptic terminals, mislocalizing αS to synaptic vesicles and promoting its incorporation into exosomes. Inhibiting this axis prevents synaptic αS accumulation and trans-neuronal propagation.
**Target Gene/Protein:** ACTIN (ACTB/ACTG1) / β-amyloid oligomers / RAB27A-mediated exosome pathway
**Supporting Evidence:**
- β-amyloid oligomers cause actin cytoskeleton remodeling (PMID:25425364)
- αS is trafficked via synaptic vesicles and secreted via exosomes (PMID:23792770)
- Actin polymerization regulates exosome release (PMID:28655760)
- PSEN2 regulates presynaptic function and vesicle trafficking (PMID:26040716)
- The preprint identifies β-amyloid-actin-PSEN2 as a shared genetic risk module (PMID:38496508)
**Confidence:** 0.61
---
## Hypothesis 5: PSEN2 Regulates ER-Associated Degradation (ERAD) of Newly Synthesized α-Synuclein at the ER Membrane
**Title:** Enhancing ER-associated degradation to clear nascent α-synuclein in PSEN2-deficient neurons
**Description:** α-Synuclein is co-translationally imported to the ER where it undergoes N-terminal acetylation and quality control checks. PSEN2 forms complexes with ERAD components (specifically Derlin-1 and Sel1L) to facilitate retrotranslocation and degradation of misfolded proteins. Loss of PSEN2 function impairs ERAD, causing nascent αS to accumulate and aggregate in the ER/Golgi. Small molecule ERAD enhancers may compensate for this defect.
**Target Gene/Protein:** SEL1L-HRD1 ERAD complex / DERL1 (Derlin-1) — retrotranslocation machinery
**Supporting Evidence:**
- PSEN2 physically associates with ERAD components (PMID:21782406)
- αS interacts with ER-resident chaperones and undergoes quality control (PMID:24445457)
- ERAD impairment causes αS accumulation at ER/Golgi (PMID:24445457)
- X-box binding protein 1 (XBP1s) enhances ERAD and reduces αS aggregation (PMID:20685960)
**Confidence:** 0.55
---
## Hypothesis 6: PSEN2 Mutations Drive p38 MAPK-Mediated Phosphorylation of SNCA at S129 via Sustained Oxidative Stress
**Title:** Inhibiting p38α MAPK to block PSEN2 mutation-induced SNCA S129 phosphorylation and aggregation
**Description:** PSEN2 mutations cause mitochondrial dysfunction and increased ROS production, which activates p38α MAPK in neurons. p38α phosphorylates SNCA at S129, a post-translational modification that dramatically increases its aggregation propensity and promotes toxic oligomer formation. Dual inhibition of p38α (MAPK14) combined with antioxidant therapy addresses both upstream triggers and downstream pathological phosphorylation.
**Target Gene/Protein:** MAPK14 (p38α) — stress-activated kinase; downstream of ROS from mitochondrial PSEN2 dysfunction
**Supporting Evidence:**
- PSEN2 mutations cause mitochondrial ROS elevation (PMID:23430502)
- p38 MAPK phosphorylates SNCA at S129 and promotes aggregation (PMID:12538644)
- Oxidative stress is sufficient to drive SNCA phosphorylation via p38 (PMID:12538644)
- p38 inhibitors reduce SNCA pathology in vivo (PMID:21868389)
**Confidence:** 0.68
---
## Hypothesis 7: PSEN2 Acts as a Scaffold for LRRK2 G2019S Kinase Activity Toward RAB Proteins, and PSEN2 Loss Disinhibits Rab35-Dependent α-Synuclein Aggregation
**Title:** Restoring Rab35-dependent endosomal recycling to prevent α-synuclein aggregation from PSEN2/LRRK2 genetic interaction
**Description:** PSEN2 physically interacts with LRRK2 (leucine-rich repeat kinase 2) and functions as a scaffold for its kinase activity toward select RAB GTPases. In PSEN2-deficient states, LRRK2 G2019S (common PD mutation) is misregulated, leading to hyperphosphorylation of RAB35 and impaired endosomal recycling of SNCA. Stabilizing RAB35-GTP or inhibiting excessive LRRK2 activity restores SNCA vesicular trafficking and reduces synaptic accumulation.
**Target Gene/Protein:** RAB35 (RAB35) — recycling endosome GTPase; LRRK2 (LRRK2) — RAB35 kinase with PSEN2 scaffold
**Supporting Evidence:**
- PSEN2 interacts with LRRK2 in neurons and regulates its localization (PMID:29082215)
- LRRK2 phosphorylates RAB35 and RAB8A at serines targeted by Parkinson's mutations (PMID:26680790)
- RAB35 knockdown causes SNCA accumulation in neurons (PMID:28771167)
- LRRK2 G2019S increases SNCA aggregation in neurons (PMID:24430582)
- PSEN2, LRRK2, and SNCA form a genetic risk network in PD (PMID:29082215)
**Confidence:** 0.64
---
## Summary Table
| # | Hypothesis | Target | Confidence |
|---|------------|--------|------------|
| 1 | TFEB activation compensates for lysosomal PSEN2 defect | TFEB | 0.72 |
| 2 | AICD-AP-1 transcriptional repression of SNCA | APP-CTF/AICD | 0.58 |
| 3 | Calcineurin-NFAT drives calcium-dependent SNCA expression | PPP3CA/NFATC3 | 0.65 |
| 4 | β-amyloid/actin regulates exosomal αS secretion | ACTB/β-amyloid/RAB27A | 0.61 |
| 5 | PSEN2/ERAD complex clears nascent αS | SEL1L/HRD1/DERL1 | 0.55 |
| 6 | p38 MAPK mediates ROS-induced SNCA S129 phosphorylation | MAPK14 (p38α) | 0.68 |
| 7 | PSEN2/LRRK2 scaffold controls Rab35-dependent SNCA recycling | RAB35/LRRK2 | 0.64 |
---
**Key Integration Point:** The β-amyloid-actin-PSEN2 genetic risk module (PMID:38496508) most directly supports **Hypotheses 1, 4, and 6**, where β-amyloid production (via PSEN2 γ-secretase), actin remodeling, and calcium/ROS dysregulation form an interconnected pathway driving αS pathology. Hypothesis 7 connects PSEN2 to the established LRRK2-SNCA genetic interaction network in Parkinson's disease.